Table 1 Genetic variation, co-receptor usage and clinical information for the different infants included in this study

2

26

21

0.6

0.3

0.71

21(18–21)

330(330-330)

CCR5

4

44

37

1.1

0.5

1.15

21(20–22)

330(323–330)

8

43

42

1.9

0.8

1.37

21(19–23)

328(327–330)

CCR5

Pneumonia

2

30

29

1.1

0.6

0.61

25(23–25)

339(335–339)

CCR5

6

33

33

1.3

0.7

0.66

25(23–26)

337(329–339)

CCR5

Bronchitis

2

29

26

1.2

0.6

0.91

28(27–29)

356(356-356)

CCR5

4

29

27

1.0

0.5

0.77

28(27–28)

356(356-356)

CCR5

Tuberculosis

2

27

27

1.1

0.6

0.52

23(22–24)

336(336-336)

4

23

23

1.3

0.8

0.41

23(22–24)

336(336-336)

6

26

26

1.8

1.0

0.69

24(23–24)

336(336-336)

CCR5

Pyrexia

4

25

25

2.1

1.0

0.97

21(19–22)

343(343-343)

6

27

26

1.7

0.7

1.21

22(20–24)

342(332–343)

CCR5

12

27

27

2.8

1.3

0.94

23(21–24)

340(331–343)

CCR5

24

26

26

4.2

2.0

0.98

24(22–26)

329(325–340)

CCR5

36

29

27

5.4

2.6

1.04

24(22–26)

332(326–341)

CCR5

48

26

26

6.6

3.3

1.02

24(22–26)

331(323–344)

CCR5

6

25

25

2.4

1.2

0.68

21(19–23)

319(319–328)

27

28

28

1.3

0.7

0.65

25(24–25)

328(328-328)

CCR5

36

25

24

5

2.6

1.1

25(22–28)

336(325–344)

CCR5

48

48

40

8.9

4.9

0.76

27(18–28)

344(325–344)

CCR5

12

28

28

1.8

1.0

0.71

26(23–27)

338(331–339)

CCR5

24

31

31

2.1

1.1

0.65

23(22–25)

329(325–336)

36

30

30

3.0

1.7

0.72

23(19–25)

327(319–338)

48

26

26

4.4

2.2

1.01

24(23–26)

336(331–341)

CXCR4/CCR5